Association of amyloid reduction after donanemab treatment with tau pathology and clinical outcomes: the TRAILBLAZER-ALZ randomized clinical trial
S Shcherbinin, CD Evans, M Lu, SW Andersen… - JAMA …, 2022 - jamanetwork.com
Importance β-amyloid plaques and neurofibrillary tau deposits biologically define Alzheimer
disease. Objective To perform post hoc analyses of amyloid reduction after donanemab …
disease. Objective To perform post hoc analyses of amyloid reduction after donanemab …
Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes
S Shcherbinin, CD Evans, M Lu, SW Andersen… - JAMA …, 2022 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> Importance</jats: title>< jats: p> β-amyloid plaques and
neurofibrillary tau deposits biologically define Alzheimer disease.</jats: p></jats: sec>< jats …
neurofibrillary tau deposits biologically define Alzheimer disease.</jats: p></jats: sec>< jats …
Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial.
S Shcherbinin, CD Evans, M Lu, SW Andersen… - JAMA …, 2022 - europepmc.org
Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and
Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial. - Abstract - Europe …
Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial. - Abstract - Europe …
Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial
S Shcherbinin, CD Evans, M Lu… - JAMA …, 2022 - pubmed.ncbi.nlm.nih.gov
Importance β-amyloid plaques and neurofibrillary tau deposits biologically define Alzheimer
disease. Objective To perform post hoc analyses of amyloid reduction after donanemab …
disease. Objective To perform post hoc analyses of amyloid reduction after donanemab …
Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes The TRAILBLAZER-ALZ Randomized Clinical Trial
S Shcherbinin, CD Evans, M Lu, SW Andersen… - jamanetwork.com
OBJECTIVE To perform post hoc analyses of amyloid reduction after donanemab treatment
and assess its association with tau pathology and clinical measures. DESIGN, SETTING …
and assess its association with tau pathology and clinical measures. DESIGN, SETTING …
Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial.
S Shcherbinin, CD Evans, M Lu… - JAMA …, 2022 - search.ebscohost.com
This post hoc analysis of the randomized clinical trial, Study of LY3002813 in Participants
With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ), investigates if amyloid …
With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ), investigates if amyloid …
[HTML][HTML] Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial
S Shcherbinin, CD Evans, M Lu, SW Andersen… - JAMA …, 2022 - ncbi.nlm.nih.gov
Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and
Clinical Outcomes - PMC Back to Top Skip to main content NIH NLM Logo Access keys …
Clinical Outcomes - PMC Back to Top Skip to main content NIH NLM Logo Access keys …
Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial.
S Shcherbinin, CD Evans, M Lu, SW Andersen… - JAMA …, 2022 - europepmc.org
Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and
Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial. - Abstract - Europe …
Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial. - Abstract - Europe …